Erratum: Targeting CD137 enhances the efficacy of cetuximab(J Clin Invest. (2019)129:6 (2595-2595) DOI: 10.1172/JCI129689)

Holbrook E. Kohrt, A. Dimitrios Colevas, Roch Houot, Kipp Weiskopf, Matthew J. Goldstein, Peder Lund, Antonia Mueller, Idit Sagiv-Barfi, Aurelien Marabelle, Ruth Lira, Emily Troutner, Lori Richards, Amanda Rajapaska, Jonathan Hebb, Cariad Chester, Erin Waller, Anton Ostashko, Wen Kai Weng, Lieping Chen, Debra CzerwinskiYang Xin Fu, John Sunwoo, Ronald Levy

Research output: Contribution to journalComment/debate

Abstract

Stanford University School of Medicine recently notified the JCI of concerns regarding Figure 4, B, C, and E, Figure 5, B, D, and F, and Figure 6B and indicated that the original source data for these figures could not be located. In accordance with the institutional recommendation, the JCI is retracting this article.

Original languageEnglish (US)
Number of pages1
JournalJournal of Clinical Investigation
Volume129
Issue number6
DOIs
StatePublished - Jun 3 2019

    Fingerprint

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Kohrt, H. E., Colevas, A. D., Houot, R., Weiskopf, K., Goldstein, M. J., Lund, P., Mueller, A., Sagiv-Barfi, I., Marabelle, A., Lira, R., Troutner, E., Richards, L., Rajapaska, A., Hebb, J., Chester, C., Waller, E., Ostashko, A., Weng, W. K., Chen, L., ... Levy, R. (2019). Erratum: Targeting CD137 enhances the efficacy of cetuximab(J Clin Invest. (2019)129:6 (2595-2595) DOI: 10.1172/JCI129689). Journal of Clinical Investigation, 129(6). https://doi.org/10.1172/JCI73014